Orgenesis Inc
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of res… Read more
Market Cap & Net Worth: Orgenesis Inc (ORGS)
Orgenesis Inc (OTCQB:ORGS) has a market capitalization of $13.03 Million ($13.03 Million) as of March 19, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #28724 globally and #9555 in its home market, demonstrating a -21.25% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Orgenesis Inc's stock price $2.52 by its total outstanding shares 5171310 (5.17 Million).
Orgenesis Inc Market Cap History: 2015 to 2025
Orgenesis Inc's market capitalization history from 2015 to 2025. Data shows change from $198.58 Million to $13.03 Million (-26.75% CAGR).
Orgenesis Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Orgenesis Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
48.85x
Orgenesis Inc's market cap is 48.85 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $198.58 Million | $2.97 Million | -$4.46 Million | 66.77x | N/A |
| 2016 | $192.43 Million | $6.40 Million | -$9.19 Million | 30.08x | N/A |
| 2017 | $297.61 Million | $10.09 Million | -$12.37 Million | 29.50x | N/A |
| 2018 | $242.02 Million | $18.66 Million | -$18.29 Million | 12.97x | N/A |
| 2018 | $242.02 Million | $18.66 Million | -$18.29 Million | 12.97x | N/A |
| 2019 | $240.98 Million | $33.26 Million | -$26.04 Million | 7.25x | N/A |
| 2020 | $232.71 Million | $7.65 Million | -$95.13 Million | 30.41x | N/A |
| 2021 | $148.93 Million | $35.50 Million | -$18.06 Million | 4.20x | N/A |
| 2022 | $100.84 Million | $36.02 Million | -$12.17 Million | 2.80x | N/A |
| 2023 | $25.89 Million | $530.00K | -$55.36 Million | 48.85x | N/A |
Competitor Companies of ORGS by Market Capitalization
Companies near Orgenesis Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Orgenesis Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Orgenesis Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Orgenesis Inc's market cap moved from $198.58 Million to $ 13.03 Million, with a yearly change of -26.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $13.03 Million | +115.38% |
| 2024 | $6.05 Million | -76.63% |
| 2023 | $25.89 Million | -74.32% |
| 2022 | $100.84 Million | -32.29% |
| 2021 | $148.93 Million | -36.00% |
| 2020 | $232.71 Million | -3.43% |
| 2019 | $240.98 Million | -0.43% |
| 2018 | $242.02 Million | -18.68% |
| 2017 | $297.61 Million | +54.65% |
| 2016 | $192.43 Million | -3.09% |
| 2015 | $198.58 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Orgenesis Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.03 Million USD |
| MoneyControl | $13.03 Million USD |
| MarketWatch | $13.03 Million USD |
| marketcap.company | $13.03 Million USD |
| Reuters | $13.03 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.